• Blueprint Medicines Corp BPMC.OQ reported a quarterly adjusted loss of 79 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.82. The mean expectation of twenty analysts for the quarter was for a loss of 70 cents per share. Wall Street expected results to range from $-1.24 to -51 cents per share.

• Revenue rose 103.4% to $146.37 million from a year ago; analysts expected $145.84 million.

• Blueprint Medicines Corp's reported EPS for the quarter was a loss of 79 cents​.

• The company reported a quarterly loss of $49.96 million.

• Blueprint Medicines Corp shares had risen by 18.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.9% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Blueprint Medicines Corp is $128.50

This summary was machine generated from LSEG data February 13 at 03:14 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)